Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

naquotinib (ASP8273)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Astellas

Drug class:

EGFR inhibitor

Related drugs:

‹

cetuximab (347)

osimertinib (301)

erlotinib (235)

gefitinib (194)

panitumumab (123)

lapatinib (107)

neratinib (102)

brigatinib (50)

aumolertinib (39)

amivantamab-vmjw (25)

firmonertinib (14)

mobocertinib (12)

lazertinib (12)

tarloxotinib bromide (7)

nimotuzumab (6)

rociletinib (5)

tomuzotuximab (4)

necitumumab (3)

befotertinib (3)

zorifertinib (3)

ABP 494 (cetuximab biosimilar) (1)

BAY 2927088 (1)

Compound 6a (1)

abivertinib (1)

STI-001 (cetuximab biosimilar) (0)

antroquinonol (0)

zalutumumab (0)

JNJ-26483327 (0)

PF-08046052 (0)

rindopepimut (0)

Undisclosed EGFR inhibitor (0)

cetuximab biosimilar (0)

PF-06747775 (0)

JNJ-64041757 (0)

›

EGFR T790M	Non Small Cell Lung Cancer	EGFR T790M	Non Small Cell Lung Cancer	ASP8273 Sensitive: C2 – Inclusion Criteria ASP8273 Sensitive : C2	ASP8273 Sensitive: C2 – Inclusion Criteria ASP8273 Sensitive : C2
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	ASP8273 Sensitive: C2 – Inclusion Criteria ASP8273 Sensitive : C2	ASP8273 Sensitive: C2 – Inclusion Criteria ASP8273 Sensitive : C2
AXL overexpression	Non Small Cell Lung Cancer	AXL overexpression	Non Small Cell Lung Cancer	ASP8273 Sensitive: D – Preclinical ASP8273 Sensitive : D	ASP8273 Sensitive: D – Preclinical ASP8273 Sensitive : D